Gamma Medica Inc.
RELATED CONTENT
Gamma Medica Inc. announced the CE Mark approval allowing for the sale and distribution of the LumaGEM Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA.
October 14, 2015 
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for the highest share of the global nuclear medicine diagnostic market, followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in the diagnostic sector because of increasing diagnostic procedure demand and the rise of the medical device industry.
June 29, 2015 
Breast cancer is the second leading cause of cancer deaths among women in developed countries.[1] It is estimated that about 12 percent of women in the United States will develop invasive breast cancer over the course of their lifetime and more than 200,000 new cases of invasive breast cancer are expected to be diagnosed in 2015.[2] It is important to know the risks and warning signs of breast cancer, and having the benefit of early detection is invaluable, but sometimes that’s easier said than done.
April 01, 2015 
A study conducted by Mayo Clinic and published in the AJR has clinically confirmed that Molecular Breast Imaging (MBI) yields superior imaging and low radiation exposure for women with dense breast tissue, which can affect up to 40 percent of the female population.
January 27, 2015 
Gamma Medica announced a new strategic partnership with Volpara Solutions.
December 04, 2014 Gamma Medica announced the company now offers Philips MicroDose SI, the first full-field digital mammography (FFDM) system that supports single-shot, non-invasive spectral imaging, as a complement to its market leading LumaGEM Molecular Breast Imaging (MBI) system. LumaGEM is a highly effective and cost-efficient technology for detecting breast cancer in patients with complex mammograms and dense breast tissue. The agreement with Philips will enable Gamma Medica to provide breast imaging suites with the option to purchase both technologies and offer the most advanced and safest commercially available dense breast solution for women. Philips will continue selling MicroDoseSI directly to customers.
November 24, 2014 
Congresswoman Annie Kuster (NH-02) met Jan. 21 with executives from Gamma Medica to discuss the Breast Density and Mammography Reporting Act. Kuster recently cosponsored the bill in an effort to promote better breast cancer detection and prevention, and to help provide women with the tools to make informed health decisions.
February 10, 2014 
Gamma Medica Inc., developer and marketer of the LumaGEM molecular breast imaging (MBI) system, announced new headquarters and manufacturing facilities in Salem, N.H., supporting expanded commercialization of its LumaGem system and LumaGuide MBI-guided biopsy module.
October 29, 2013 
Gamma Medica announced the updated LumaGEM Molecular Breast Imaging (MBI) system.
October 04, 2013 
Gamma Medica Inc. has closed a $16 million Series A financing round from healthcare investment firm Psilos Group Managers, LLC. This investment will enable Gamma Medica to expand commercialization of the LumaGEM Molecular Breast Imaging (MBI) system and its companion product the LumaGUIDE MBI-guided biopsy module.
July 18, 2013